liuxiaofeng - Lyvgen Biopharma Website 礼进生物英文官网

News
Lyvgen Appoints Xiaofeng Liu, Ph.D. as Senior Vice President of Manufacturing & Drug Development

Suzhou, China, October 19, 2020 – Lyvgen Biopharma, a biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, is pleased to announce today the appointment of Xiaofeng Liu, Ph.D. as Senior Vice President of Manufacturing & Drug Development. This appointment forms part of Lyngen’s strategic drive to strengthen CMC capabilities including GMP manufacturing.

Dr. Liu will provide leadership and oversight of Lyvgen CMC operation and development, including process and analytical development, qualification and validation strategies, planning and execution. As a Ph.D. in Biochemistry, Dr. Liu brings near 20 years management and technical experience in executions of more than 20 biologics at all CMC development stages, from preclinical to BLA filing, in immune-oncology, autoimmune, metabolic diseases, and rare diseases. Prior to joining Lyvgen, Dr. Liu held senior leadership positions at Epitomics, Armo Biosciences, Versartis, Nektar Therapeutics and Sutro Biopharma.

"I am very pleased to welcome Dr. Liu to Lyvgen. His enriched experiences in drug product development will make significant contribution to Lyvgen, ensuring successful development and manufacturing of drug products from our innovative research pipeline" said Dr. Jieyi Wang, Founder and Chief Executive Officer of Lyvgen.

"Lyvgen is a mission-driven organization with incredible preclinical and clinical pipeline to allow me to bring new innovations into drug product development, which is well aligned with my personal and professional values. I am excited to join the Lyvgen and contribute significantly to the company's long-term development strategy."

About Lyvgen (www.lyvgen.com)
LYVGEN is an innovative biopharmaceutical company focused on research and development of novel therapies for cancer. Its proprietary xLinkAb functional platform enables discovery and development of agonistic antibodies with tumor-localized immune co-stimulatory activities by balancing multiple functions of candidate antibodies, including anti-CD137/4-1BB agonist monoclonal antibody LVGN6051 and anti-CD40 (LVGN7409) candidates presently in clinical development.
LYVGEN employs over 50 scientists with global pharmaceutical research and development experience at its research sites in China and the USA.

For additional information, please visit: https://www.lyvgen.com
Contact us